February 1, 2019 / 6:09 AM / 23 days ago

BRIEF-Newron Completes Patient Enrollment In Pivotal STARS Study

Feb 1 (Reuters) - NEWRON PHARMACEUTICALS SPA:

* TOP LINE RESULTS EXPECTED IN Q4 2019

* POSITIVE STUDY RESULTS MAY LEAD TO APPROVAL OF FIRST DRUG TO BENEFIT A KEY SYMPTOM OF RETT SYNDROME, A SEVERE NEURO-DEVELOPMENTAL ORPHAN DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below